Nektar Therapeutics (NKTR) AI Stock Analysis

Company Guidance

Management provided detailed 2026 financial and program guidance: at quarter end cash and investments were $1.02B (after an April underwritten offering that yielded $350M net), year‑end cash is now expected to be ~$815–$840M with a cash runway into Q3 2028; Q2 non‑cash royalty revenue was $10.1M and full‑year revenue is guided to $40–45M; Q2 R&D was $39.1M with full‑year R&D planned at $210–230M (including $5–10M noncash), Q2 G&A was $12.8M with full‑year G&A guided to $60–65M (including ~$5M noncash), Q2 noncash interest was $7.2M with full‑year noncash interest of ~$30–35M, and Q2 net loss was $40.6M (‑$1.23 per share). On the clinical side, Zenith AD Phase 3 began in July and is enrolling two pivotal ~510‑patient (adolescent/adult ≥12) studies randomized 2:1 to rezpeg 24 μg/kg q2w (24‑week induction + 28‑week maintenance evaluating monthly and quarterly dosing), a treatment‑experienced study starts by end‑September, top‑line AD Phase 3 data are expected mid‑2028 with a potential BLA submission in 2029; ZENITH AA (single registrational AA Phase 3) is planned to start early 2027 with ~850 patients randomized 2:1 (24 μg/kg q2w through 52 weeks) and data expected H2 2029; key earlier readouts include RESOLVE AA 24‑week off‑treatment data in Q4 and RESOLVE AD 52‑week off‑treatment data in Q1 next year, and management highlighted Phase 2/Phase 1 durability signals (up to ~9 months off‑treatment after 12 weeks, and up to a 5‑fold increase in EASI‑100 during a 36‑week maintenance period).